Healthcare provider profile · identity verified

Ewa M Paszkiewicz, MD

Family Practice · RIPON, WI · NPI 1710146097

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	271	72
Atorvastatin Calcium	Atorvastatin Calcium	189	49
Levothyroxine Sodium	Levothyroxine Sodium	169	39
Omeprazole	Omeprazole	166	46
Simvastatin	Simvastatin	157	41
Rosuvastatin Calcium	Rosuvastatin Calcium	151	45
Amlodipine Besylate	Amlodipine Besylate	129	34
Losartan Potassium	Losartan Potassium	128	42
Hydrochlorothiazide	Hydrochlorothiazide	114	32
Metoprolol Succinate	Metoprolol Succinate	97	27
Albuterol Sulfate Hfa	Albuterol Sulfate	85	26
Potassium Chloride	Potassium Chloride	84	23
Eliquis	Apixaban	83	18
Metformin Hcl Er	Metformin Hcl	73	21
Gabapentin	Gabapentin	72	29
Pravastatin Sodium	Pravastatin Sodium	72	17
Citalopram Hbr	Citalopram Hydrobromide	66	17
Allopurinol	Allopurinol	64	17
Escitalopram Oxalate	Escitalopram Oxalate	63	11
Warfarin Sodium	Warfarin Sodium	63	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	56	16
Metformin Hcl	Metformin Hcl	54	20
Pantoprazole Sodium	Pantoprazole Sodium	50	18
Furosemide	Furosemide	49	14
Atenolol	Atenolol	44	12
Sertraline Hcl	Sertraline Hcl	44	12
Tamsulosin Hcl	Tamsulosin Hcl	38	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	suppressed
Jardiance	Empagliflozin	34	12
Montelukast Sodium	Montelukast Sodium	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	28	13
Fenofibrate	Fenofibrate	27	suppressed
Unifine Safecontrol Pen Needle	Pen Needle,dual Safety,diabetc	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	suppressed
Temazepam	Temazepam	24	suppressed
Famotidine	Famotidine	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Synthroid	Levothyroxine Sodium	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	13
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Glipizide	Glipizide	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	12
Amoxicillin	Amoxicillin	16	15
Estradiol	Estradiol	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Risedronate Sodium	Risedronate Sodium	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Cephalexin	Cephalexin	12	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Serevent Diskus	Salmeterol Xinafoate	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	12
Valacyclovir	Valacyclovir Hcl	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Verapamil Sr	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error